Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib

Journal of Clinical Oncology

Volumn 30, Issue 19, 2012, Pages

  Anforth, Rachael ^a,b   Cristina, Tatiana ^a   Blumetti, Moraes Pinto ^a   Affandi, Azura Mohd ^a   Fernandez Penas, Pablo ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; ETRETIN; VEMURAFENIB;

ACTINIC KERATOSIS; AGED; ANAMNESIS; ARTICLE; CASE REPORT; HISTOPATHOLOGY; HUMAN; HYPERKERATOSIS; KERATOACANTHOMA; MALE; NON MELANOMA SKIN CANCER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE;

ACITRETIN; AGED; CARCINOMA, SQUAMOUS CELL; HUMANS; INDOLES; KERATOLYTIC AGENTS; MALE; MELANOMA; RETINOIDS; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84864021610     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.8594     Document Type: Article

References (17)

1. Long GV, Menzies AM, Nagrial AM, et al: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29:1239-1246, 2011
2. Dhomen N, Marais R: BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 23:529-545, ix, 2009
3. Robert C, Arnault JP, Mateus C: RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 23:177-182, 2011
4. Lacouture ME, Chapman PB, Ribas A, et al: Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. J Clin Oncol 29:531s, 2011 (suppl 15; abstr 8520)
5. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
6. Gollinick H, Dummler U: Retinoids. Clin Dermatol 15:799-810, 1997
7. Marquez C, Bair SM, Smithberger E, et al: Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients. J Drugs Dermatol 9:753-758, 2010
8. Wright TI, Spencer JM, Flowers FP: Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol 54:933-946; quiz 947-950, 2006
9. Chambon P: The retinoid signaling pathway: Molecular and genetic analyses. Semin Cell Biol 5:115-125, 1994
10. Shuttleworth D, Marks R, Griffin PJ, et al: Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 68:717-725, 1988
11. Bavinck JN, Tieben LM, Van der Woude FJ, et al: Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: A double-blind, placebo-controlled study. J Clin Oncol 13:1933-1938, 1995
12. McNamara IR, Muir J, Galbraith AJ: Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation. J Heart Lung Transplant 21:1201-1205, 2002 (Pubitemid 35300466)
13. De Graaf YG, Euvrard S, Bouwes Bavinck JN: Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg 30:656-661, 2004 (Pubitemid 38525897)
14. Harwood CA, Leedham-Green M, Leigh IM, et al: Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: A 16-year retrospective study. Arch Dermatol 141:456-464, 2005 (Pubitemid 40547404)
15. Marquez CB, Smithberger EE, Bair SM, et al: Multiple keratoacanthomas arising in the setting of sorafenib therapy: Novel chemoprophylaxis with bexarotene. Cancer Control 16:66-69, 2009
16. van de Kerkhof PC: Update on retinoid therapy of psoriasis in: An update on the use of retinoids in dermatology. Dermatol Ther 19:252-263, 2006
17. Ormerod AD, Campalani E, Goodfield MJ: British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 162:952-963, 2010